SUN PHARMACEUTICAL INDUSTRIES INC: Drug Recall

Recall #D-0262-2023 · 01/13/2023

Class II: Risk

Recall Details

Recall Number
D-0262-2023
Classification
Class II
Product Type
Drug
Recalling Firm
SUN PHARMACEUTICAL INDUSTRIES INC
Status
Terminated
Date Initiated
01/13/2023
Location
Princeton, NJ, United States
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
Lot # HAC3120A: 6912 Bottles; Lot # HAC3121A: 6792 Bottles; Lot # HAC4460A: 6816 Bottles; Lot # HAD0365A: 6744 Bottles; Lot # HAD1452A: 6840 Bottles

Reason for Recall

Failed Impurity (Deacetyl Diltiazem Hydrochloride) specification during stability testing and failed dissolution testing at FDA laboratory.

Product Description

Diltiazem Hydrochloride Extended-Release Capsules, USP, 360 mg; Rx only; 90-count bottles, Manufactured by: Sun Pharmaceutical Industries Ltd. Halol-Baroda Highway, Halol-389350, Gujarat, India; Distributed by: Sun Pharmaceutical Industries, Inc. Cranbury, NJ 08512, NDC 47335-679-81

Distribution Pattern

Nationwide in the U.S.

Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.